



KaloBios Pharmaceuticals (S. San Francisco, CA, USA) has named **Néstor A. Molfino** (left) as chief medical officer. He was most recently vice president, clinical development and respiratory therapeutic area head at MedImmune (now owned by AstraZeneca).

“Néstor Molfino joins KaloBios with 18 years of experience directing clinical development at leading international biopharmaceutical companies, both in the United States and Canada,” says David Pritchard, KaloBios’ president and CEO.

“His strong expertise in pulmonary medicine will be particularly beneficial in advancing our clinical development of KB001-A in cystic fibrosis and KB003 in severe asthma.”

in 2008. In addition, Amicus has announced the re-election of directors **Donald J. Hayden, Jr.**, **Sol J. Barer** and **James N. Topper** to its board.

**Damian Marron** has been named CEO of privately held Cytheris (Paris). He previously served in the same capacity at Trophos.

Industry veteran **Nissim Mashiach** has been named president and CEO of MacroCure (Petach Tikva, Israel). Mashiach most recently served as general manager at Ethicon, a Johnson & Johnson company. He previously served as president and COO at Omrix Biopharmaceuticals, which was acquired by J&J for \$438 million in 2008.

Merrimack Pharmaceuticals (Cambridge, MA, USA) has named **John Mendelsohn** to the position of board director. Mendelsohn is a past president of The University of Texas MD Anderson Cancer Center. He also remains on the faculty, serving as co-director of the recently opened Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy.

Paratek Pharmaceuticals (Boston) has announced the promotion of **Dennis Molnar** from vice president, corporate development to president, CEO and director, succeeding former CEO Thomas J. Bigger, who resigned earlier this year. Molnar joined Paratek in 2001. In addition, **Evan Loh** has joined the company as chief medical officer and as chairman of the board of directors. Outgoing chairman **Walter Gilbert** will continue to serve on the board as vice chairman. Loh was formerly senior vice president, development and strategic operations, worldwide R&D at Pfizer and vice president, clinical R&D at Wyeth.

**Christine Placet** has been appointed CEO of Trophos (Marseille, France) under a previously defined internal succession plan. She had served as CFO at Trophos since 2004.

**Stephen Webster** has been appointed CFO at Optimer Pharmaceuticals (San Diego). Previously, he served as CFO of Adolor until its sale to Cubist Pharmaceuticals. From 2007 until joining Adolor in 2008, Webster was managing director, investment banking division in the health care group at Broadpoint Capital.

Shire (Dublin) has announced the promotion of senior vice president **David Colpman**, who will assume responsibility for leading Shire’s global business development team. Colpman has over 12 years of experience with Shire. He previously worked at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals in a variety of business development and commercial roles.

**Christine Cournoyer** has been named CEO of personalized cancer care company N-of-One (Waltham, MA, USA). Cournoyer brings more than 25 years of executive leadership experience with healthcare technology companies, most recently as president and COO of Picis prior to its acquisition by United Healthcare in 2010. N-of-One founder **Jennifer Levin Carter** remains as president and has assumed the additional role of chief medical officer.

Agbiotech company Devgen (Ghent, Belgium) has appointed **Ruth Devenyns** to be an independent director on its board. Devenyns is a former analyst and investment banker, having led venture capital activities in the biotech sector at KBC Private Equity until end of March 2012. She currently serves as an independent director at MDx Health and as director of FlandersBio.

Flexion Therapeutics (Woburn, MA, USA) has named **Arthur J. Fratamico** as its first chief business officer. Fratamico has more than 13 years of business development experience, having led the business development efforts for Trevena, Gemin X Pharmaceuticals and MGI Pharma.

Achillion Pharmaceuticals (New Haven, CT, USA) has announced the appointment of **Kurt Graves** to its board of directors, replacing **Nicholas Simon** of Clarus Ventures. Graves

currently serves as chairman, president and CEO of Intarcia Therapeutics, chairman of the board of Radius and a director of Pulmatrix and Springleaf Therapeutics. From 2007 through 2009 he was executive vice president, head of corporate and strategic development and chief commercial officer at Vertex Pharmaceuticals. In addition, Achillion has announced the resignation of **Elizabeth A. Olek**, senior vice president of clinical development and chief medical officer. **Milind Deshpande**, president of R&D and CSO, will assume responsibility for the oversight of ongoing and planned clinical trials evaluating Achillion’s portfolio of compounds.

Cytos Biotechnology (Zurich) has announced the nomination of **Christian Itin** to its board. Itin was formerly president and CEO of Micromet, which was acquired in March 2012 by Amgen for \$1.16 billion. Prior to joining Micromet in 1999, he co-founded protein chip company Zyomyx.

**Paul Karila** has been named head of discovery services for Cellectricon (Gothenburg, Sweden). He brings extensive drug discovery industry experience, having held several management positions at AstraZeneca.

Amicus Therapeutics (Cranbury, NJ, USA) has announced the appointments of **Ted W. Love** and **Robert Essner** to its board of directors. Love is currently executive vice president and head of R&D and technical operations at Onyx Pharmaceuticals. From 2001 to 2009 he served as CEO of Nuvelo and served as chairman and CEO from 2005 to 2009. Essner is senior advisor to the global healthcare group at The Carlyle Group, a global private equity firm. He retired as chairman and CEO of Wyeth, now part of Pfizer,